Results 251 to 260 of about 158,005 (297)
Some of the next articles are maybe not open access.
An update on lipid-lowering therapy
Current Opinion in Lipidology, 1995New information on the effects of lipid-lowering drugs is reviewed with an emphasis on special groups that benefit from specific drug therapy. Although it has been shown that the diet may further enhance the effectiveness of lipid-lowering drugs, compliance to diet and drugs remains an important issue and the large individual variations in dietary ...
J D, Barth, G B, Mancini
openaire +2 more sources
Lipid Lowering Therapy in Atherosclerosis
Seminars in Vascular Medicine, 2004Dyslipidemia plays critical roles in the pathogenesis of coronary atherosclerosis, a chronic inflammatory disease. Vascular inflammation also triggers the onset of acute complications of atherosclerosis, such as myocardial infarction. Advances in cardiovascular medicine demonstrate that lipid-lowering therapy by 3-hydroxy-3-methylglutaryl coenzyme A ...
Masanori, Aikawa, Peter, Libby
openaire +2 more sources
Journal of Stroke and Cerebrovascular Diseases, 2019 The association of lipid lowering therapy and intracerebral hemorrhage risk is controversial. We performed a cumulative meta-analysis of lipid lowering trials that reported intracerebral hemorrhage. Statin, fibrate, ezetimibe, PCSK9, and CETP trials were
Conor Judge +2 more
exaly +2 more sources
Pharmacogenomics of Lipid-Lowering Therapies
Pharmacogenomics, 2013Statins are the most widely used group of lipid-lowering drugs and they have been shown to be effective in the prevention of cardiovascular disease, primarily by reducing plasma low-density lipoprotein cholesterol concentrations and possibly through other pleiotropic effects.
Miao, Hu, Brian, Tomlinson
openaire +2 more sources
2023
Therapeutics Letter 24 is based primarily on 2 published meta-analyses and an in-house systematic review and critical appraisal of the large double-blind randomized controlled trials (RCTs) examining the impacts of lipid lowering therapy. Conclusions: Lipid lowering dietary therapy can be effective and should be a component of all treatment regimens ...
openaire +1 more source
Therapeutics Letter 24 is based primarily on 2 published meta-analyses and an in-house systematic review and critical appraisal of the large double-blind randomized controlled trials (RCTs) examining the impacts of lipid lowering therapy. Conclusions: Lipid lowering dietary therapy can be effective and should be a component of all treatment regimens ...
openaire +1 more source
Lipid-lowering therapies in development
Expert Opinion on Investigational Drugs, 2004Lipid lowering is established as a proven intervention to reduce atherosclerosis and its complications. This article summarises novel developments in the lipid-altering therapies under development, including combination therapies, squalene synthase inhibitors, microsomal transfer protein inhibitors, acyl-cholesterol acyl transferase inhibitors ...
openaire +3 more sources
Lipid-lowering therapy in diabetes mellitus
The Netherlands Journal of Medicine, 2001Dyslipidemia emerges as an important modifiable risk factor for cardiovascular disease in diabetes mellitus, especially as part of the metabolic syndrome in type 2 diabetes. In type 1 diabetes mellitus, tight glucose regulation usually will correct dyslipidemia.
S D, Niemeijer-Kanters +2 more
openaire +2 more sources
Dyslipidemia and lipid-lowering therapy in the elderly
Expert Review of Cardiovascular Therapy, 2005According to the current evidence, the fastest growing proportion of patient populations seeking healthcare is those over 65 years of age. Coronary artery disease and subclinical atherosclerosis are highly prevalent in this group of patients and are strongly linked to dyslipidemia, a well-established risk factor for atherosclerosis.
Prakash, Deedwania, Natalia, Volkova
openaire +2 more sources
Peripheral Neuropathy and Lipid-Lowering Therapy
Southern Medical Journal, 1998We report a case of a peripheral neuropathy induced and exacerbated by several commonly used HMG-CoA reductase inhibitors including lovastatin, simvastatin, pravastatin, and atorvastatin, and the vitamin niacin. A review of the literature shows similar cases with individual lipid-lowering drugs, but this case shows the cross-reactivity of the ...
P E, Ziajka, T, Wehmeier
openaire +2 more sources
Stroke prevention with lipid-lowering therapy
Expert Review of Neurotherapeutics, 2004Despite great progress in the medical sciences, the effects of stroke in the modern world are profound, both in the aspect of death and disability it causes, as well as the economic demands it poses. The most important modifiable risk factors of stroke are arterial hypertension, heart disease, cigarette smoking and transient ischemic attacks. Secondary
Piechowski-Jozwiak B, Bogousslavsky J
openaire +3 more sources